Updates

Vistry

March 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

A nice bounce to 782p means the shares are 129p above the main write-up price last December. Vistry expects FY22 pretax profit to increase c. 21% to c. £418m, in-line with expectations. Net cash is ahead of expectations at c. £115m. Synergies of at least £50m are on track from the combination with Countryside and in excess of its £19m target in FY23. During the period, housebuilding completions increased 3% to 6,774 units (FY21: 6,551), and adjusted gross margin is expected to be at least 23% (FY21: 22.3%). Forward sales total £4.6bn (31 Dec 2021: £2.7bn) including £3.6bn for the enlarged Partnerships business with strong pipeline in Partnerships and Housebuilding forward sales £1.0bn (31 December 2021: £1.3bn) ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

SigmaRoc - SigmaRoc Eps rises an incredible 40% in tough year

Somero

Vistry - Shares double since main write-up (June 2024)

Vistry (December 2023)

Vistry - Increased focus on social / affordable housing and pre-sales could double profit to £800m medium term (November 2023)

Vistry (September 2023)

Vistry (August 2023)

Vistry - Countryside synergies upgraded by £10m (May 2023)

Vistry - Transformative acquisition increases fast-growing social housing to over 50% sales (December 2022)

Vistry (April 2022)

Vistry (January 2022)

Vistry (November 2021)

Vistry (October 2021)

Vistry - Gain since last Novembers write-up: 127% (July 2021)

Vistry (April 2021)

Vistry (March 2021)

Vistry - Net debt falls from £357m to just £40m (January 2021)

Vistry (September 2020)

Vistry - Partnerships division transforms growth prospects (July 2020)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

Vistry

March 2023

Related Articles